ClinicalTrials.gg
CompletedNCT06671821Updated Nov 17, 2025

Long-term Efficacy and Safety of HRS-7535 Tablets in Obese Subjects

A Phase 2 interventional study of HRS-7535 in Chronic Weight Management, sponsored by Shandong Suncadia Medicine Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-11-17.

Sponsored by Shandong Suncadia Medicine Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
81
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The Objective of this trial is to evaluate the long-term safety, tolerability, weight loss efficacy and metabolic benefits of HRS-7535 tablets inobesity.

02

Conditions studied

  • Chronic Weight Management
03

In context

Lead sponsor

Shandong Suncadia Medicine Co., Ltd. is the lead sponsor of 87 studies on the registry; 39 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subjects, 18-65 years of age at the time of signing ;
  2. Subjects who have completed the entire 36-week treatment course of the HRS-7535-202 trial.
  3. Subjects who have a full understanding of the trial content, processes, and possible adverse reactions, and are capable and willing to comply with the protocol requirements to complete this study.

Exclusion criteria

Exclusion Criteria:

  1. Participants with poor compliance during the 36-week open-label extension treatment of the HRS-7535-202 trial;
  2. Pregnant, lactating, planning to conceive during the trial period, or fertile subjects unwilling to take effective measures during the trial period.
  3. Any other conditions deemed unsuitable for participation in this clinical trial by the investigator.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
81 participants (actual)

Study arms

  • Experimental
    Group A

    Subjects will receive escalated dose of HRS-7535 or maximum tolerated dose orally

    Drug: HRS-7535

  • Experimental
    Group B

    Subjects will receive escalated dose of HRS-7535 or maximum tolerated dose orally

    Drug: HRS-7535

  • Experimental
    Group C

    Subjects will receive escalated dose of HRS-7535 or maximum tolerated dose orally

    Drug: HRS-7535

  • Experimental
    Group D

    Subjects will receive escalated dose of HRS-7535 or maximum tolerated dose orally

    Drug: HRS-7535

Interventions

06

What researchers measure

Primary outcomes

  1. Number of participants with Treatment-emergent Adverse Event(AE)

    Time frame: During the 32-week open-label extension treatment period

Secondary outcomes

  1. Percentage change in body weight from baseline before HRS-7535 tablet treatment to Week 32 of open-label extension treatment;

    Time frame: from baseline before HRS-7535 tablet treatment to Week 32 of open-label extension treatment;

  2. Proportion of subjects with ≥5%, ≥10%, and ≥15% weight reduction from baseline before HRS-7535 tablet treatment to Week 32 of open-label extension treatment;

    Time frame: from baseline before HRS-7535 tablet treatment to Week 32 of open-label extension treatment;

  3. Changes in weight from baseline before HRS-7535 tablet treatment to Week 32 of open-label extension treatment;

    Time frame: from baseline before HRS-7535 tablet treatment to Week 32 of open-label extension treatment;

  4. Changes in waist circumference from baseline before HRS-7535 tablet treatment to Week 32 of open-label extension treatment;

    Time frame: from baseline before HRS-7535 tablet treatment to Week 32 of open-label extension treatment;

  5. Changes in body mass index (BMI) from baseline before HRS-7535 tablet treatment to Week 32 of open-label extension treatment;

    Time frame: from baseline before HRS-7535 tablet treatment to Week 32 of open-label extension treatment;

07

Study locations

1 site
  • Chinese PLA General Hospital
    Beijing, Beijing Municipality 100039, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2024 to primary completion in Aug 2025, 8 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2024
First posted
Nov 4, 2024
StartActual
Nov 20, 2024
Primary completionActual
Aug 15, 2025
CompletionActual
Sep 28, 2025
Last update
Nov 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06671821
Responsible party
Sponsor
First posted
Nov 4, 2024
Start date
Nov 20, 2024
Primary completion
Aug 15, 2025
Completion
Sep 28, 2025
Last update
Nov 17, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Safiglipron

Start the discussion